eflornithine
Selected indexed studies
- Eflornithine. (Indian J Dermatol Venereol Leprol, 2007) [PMID:17921631]
- Eflornithine for treatment of high-risk neuroblastoma. (Trends Pharmacol Sci, 2024) [PMID:38749882]
- Topical eflornithine. (Am J Clin Dermatol, 2001) [PMID:11705097]
_Worker-drafted node — pending editorial review._
Connections
eflornithine is a side effect of
Sources
- Eflornithine. (2007) pubmed
- Eflornithine for treatment of high-risk neuroblastoma. (2024) pubmed
- Topical eflornithine. (2001) pubmed
- Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review. (2024) pubmed
- Eflornithine. (2001) pubmed
- Eflornithine (Iwilfin) for high-risk neuroblastoma. (2024) pubmed
- Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. (2018) pubmed
- Enantiospecific antitrypanosomal in vitro activity of eflornithine. (2021) pubmed
- Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. (2020) pubmed
- Eflornithine for the treatment of human African trypanosomiasis. (2003) pubmed